mTOR inhibitors (everolimus · temsirolimus)
mTOR inhibitor
Podocyte injury → proteinuria and FSGS.
Rapamune · SIR
mTOR inhibitor · approved 1999 · 13 citations · FAERS AKI reporting ROR 3.65 (95% CI 3.34–3.98, 512 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An mTOR inhibitor long called 'non-nephrotoxic' that can nonetheless unmask podocyte injury, proteinuria, and stall tubular repair.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
New or worsening proteinuria occurs in a substantial minority of treated patients in transplant cohorts (more pronounced after conversion from a calcineurin inhibitor than with de novo use), but oncology-specific renal incidence is not well quantified and is described largely at the case and small-series level. Acute renal dysfunction (e.g., delayed graft recovery) is recognized but variable. Reported rate: proteinuria in 23.1% — 18 of 78 kidney, pancreas and islet transplant recipients given sirolimus de novo or after conversion, 5 of the 18 (27.8%) reaching nephrotic range; a transplant-immunosuppression figure, not an oncology one (Franco 2007, PMID 17362756).Source: Franco et al., Transplant Proc 2007 (transplant cohort, proteinuria 23.1%); Diekmann, Transplant Rev 2012
Weeks to months after initiation or dose escalation; proteinuria often worsens months after calcineurin-inhibitor conversion.
Distilled from: “Variable—weeks to months after initiation or dose escalation; proteinuria characteristically emerges or worsens within months after calcineurin-inhibitor withdrawal/conversion.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
proteinuria in ~23% of transplant recipients on sirolimus (de novo or after CNI conversion), occasionally FSGS
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Binds the immunophilin FKBP12; the sirolimus-FKBP12 complex inhibits mTOR complex 1 (mTORC1), blocking p70S6K/4E-BP1-driven protein synthesis, cell-cycle progression at the G1/S checkpoint, and pro-survival/angiogenic (VEGF) signaling. Used as an antiproliferative immunosuppressant and, within the broader mTOR-inhibitor class (with everolimus and temsirolimus), in oncology settings including renal cell carcinoma, perivascular epithelioid cell tumors, and lymphangioleiomyomatosis.
Class-level context for the major non-renal toxicities of the mTOR inhibitor class.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Endocrine
Thyroiditis, hypophysitis, diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 13,673 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
2,174 of 13,673 reports
Reported with hospitalization
4,682 of 13,673 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,944 of the 13,673 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Sirolimus sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
mTOR inhibitor
Podocyte injury → proteinuria and FSGS.
Datroway · Antibody-drug conjugate (TROP2/DXd)
2025 TROP2 ADC; renal signal theoretical, extrapolated from the ADC class.
Torisel · mTOR inhibitor
Proteinuria and glomerular effects; less firmly quantified than everolimus.
Tarceva · EGFR TKI
Rare minimal-change disease and AKI.
Clolar · Purine analog
Capillary-leak / SIRS-like AKI and tumor lysis.
Boniva · Bisphosphonate
Lower renal risk than zoledronate.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Sirolimus’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Sirolimus; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 190 clinical records among the 300 most-relevant of 1,071 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.